**Specifications table**TableSubject area*Clinical Chemistry*More specific subject area*Biomarkers of autism*Type of data*Tables and figure*How data was acquired*ELISA Technique analysis of blood samples*Data format*Analyzed data*Experimental factors*Blood was collected in test tubes containing heparin as anticoagulant. The samples were separated by centrifugation at* 3000 rpm *and* 25 °C *for* 10 *min. The plasma was removed and frozen at* −80 °C *until analyzed.*Experimental features*The selected biomarkers were measured in plasma samples of autistics and control participants*Data source location*Riyadh, Saudi Arabia, Autism Research & Treatment Center clinic*Data accessibility*All data is with this article*

**Value of the data** {#s0005}
=====================

•Identification of novel biomarker for neurological disorders will help to increase the quality of life of affected individuals, by providing sensitive and selective clinical correlates for the early diagnosis.•These markers can provide insights into disease mechanisms that can be used to identify therapeutic targets and to develop efficacious compounds to target them.•Due to the complexity of the brain, a single marker is not sufficient to have enough diagnostic power and thus it is important to combine panel of markers to improve diagnosis accuracy [@bib5].•Among different combination approaches, the multiple regressions are easy to compute and interpret the relationship between different recorded markers. It is a common statistical technique to assess the relationships among two or more independent variables and their correlation with a dependent variable.•Screening of this panel of markers in newborns at risk for neuro-developmental disease (e.g. autism) can help in the early diagnosis and intervention.

1. Data {#s0010}
=======

[Table 1](#t0005){ref-type="table"} demonstrates the significant variations of the measured parameters in autistic patients compared to healthy controls. *R*^2^ values of the multiple regression analysis for glutamate, glutamine and glutamate/glutamine ratio as three dependent variables show that almost 100% of the changes of these variables could be easily explained and associated by the changes in oxidative stress and detoxification related parameters in autistic patients but not in age and gender matching control participants ([Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"}, [Table 5](#t0025){ref-type="table"}). The relationship between the panels of associated biomarkers is illustrated in [Fig. 1](#f0005){ref-type="fig"}.

2. Experimental design, materials and methods {#s0015}
=============================================

The local Ethical Committee of the Faculty of Medicine, King Saud University, Riyadh, Saudi Arabia, approved this study (Approval number is 11/2890/IRB). In addition, an informed written consent of participation for this study was signed by the parents or the legal guardians of the investigated subjects, according to the Helsinki principles. All subjects enrolled in the study (20 autistic children and 20 control males) had filled the informed consent. They were enrolled through the ART Center (Autism Research & Treatment Center) clinic in King Khalid University Hospital in Riyadh. The ART Center clinic population consisted of children diagnosed on the autism spectrum disorder (ASD). The diagnosis of ASD was confirmed in all subjects using the Autism Diagnostic Interview-Revised (ADI-R) and the Autism Diagnostic Observation Schedule (ADOS) and Developmental, dimensional diagnostic interview (3DI). The mean of age of all autistic children participated in the study were between 7±4 years old. All were simplex cases. All were negative for fragile×gene study. The control group recruited from pediatric clinic at king Saud medical city in Riyadh with mean age 7±4 years old. Subjects were excluded from the investigation if they had dysmorphic features, or diagnosis of fragile X or other serious neurological (e.g., seizures), psychiatric (e.g., bipolar disorder) or known medical conditions. All participants were screened via parental interview for current and past physical illness. Children with known endocrine, cardiovascular, pulmonary, liver, kidney or other medical disease were excluded from the study.

2.1. Blood samples {#s0020}
------------------

After an overnight fast, patients underwent blood sampling; 10 ml blood samples were collected on ice from both groups in test tubes containing heparin as anticoagulant. The samples were separated by centrifugation at 3000 rpm and 25 °C for 10 min. The plasma was removed and frozen at −80 °C until analyzed.

3. Biochemical analyses {#s0025}
=======================

Glutamate and glutamine levels were assessed using an HPLC method. For measurement of glutamate dehydrogenase activity, a commercial kit (Randox Laboratories Ltd., Crumlin, Co. Antrim, UK) was used. Thioredoxin 1 (Trx 1) together with the peroxiredoxins (Prxs I and III) was assessed using ELISA kits, a product of northwest company. Thioredoxin reductase (TR) activity was measured using commercially available kit (Biovision, USA). Measurement of reduced GSH, total glutathione and GSH/GSSG ratio were assayed based on the glutathione recycling system by 5,5-dithio-bis (2-nitrobenzoic acid) (DTNB) and glutathione reductase. The glutathione-s-transferase (GST) activity was assessed using (Biovision, USA) assay kit. The concentration of inorganic mercury (Hg) in red blood cells was determined using a flameless atomic-absorption instrument.

3.1. Statistical analyses {#s0030}
-------------------------

Statistical Program for Social Sciences (SPSS) (SPSS Inc., Chicago, IL, USA) was used for all analyses. Data were expressed as mean±SD. All statistical comparisons were made by means of Student's *t*-test. *P*\<0.05 was considered significant. Multiple regression analysis was used to find the correlation between the selected parameters using SPSS program [@bib4]. In this analysis *R*^2^ describes the proportion or percentage of variance in the dependent variable explained by the variance in the independent variables together which sometimes called the predictor variables. An *R*^2^ of 1.00 indicates that 100% of the variation in the dependent variable is explained by the independent variables. Conversely, an *R*^2^ of 0.0 indicates the absence of variation in the dependent variable due to the independent variables. In this work as the variables are not in the same unit of measures, a standardized regression coefficient, beta (*β*), was used. The *β* coefficients values show the direction either positive or negative and the contribution of the independent variable relative to the other independent variables in explaining the variation of the dependent variable. *R*^2^ and (*β*) coefficient provide most of what we need to interpret our multiple regression data. Stepwise multiple regression analyses were performed using glutamate, glutamine and glutamate/glutamine ratio as three dependent variables and Trx1, Trxreductase, Prx I&III, GSH/GSSG, glutathione-s-transferase and mercury as independent variables.

Appendix A. Supplementary material {#s0045}
==================================

Supplementary material

This research project was supported by a grant from the Research Center of the Center for Female Scientific and Medical Colleges in King Saud University.

Supplementary data associated with this article can be found in the online version at [doi:10.1016/j.dib.2016.02.025](http://dx.doi.org/10.1016/j.dib.2016.02.025){#ir0005}.

![Illustrated relationship between the associated glutamate excitotoxicity, oxidative stress and impaired detoxification markers in autistic patients.](gr1){#f0005}

###### 

Mean±SD of the measured chemicals in plasma or red blood cells of patients with autism compared with age-matched controls.

Table 1

  ----------------------------------------- --------- ------------- -------------- ---------------- -----------
  Parameter                                 Group     *N*           Mean±SD        Percent change   *P* value
                                                                                                    
  Glutamic (µmol/l)                         Control   20            111.91±4.51    100.00           0.001
  Autistic                                  20        152.80±6.47   136.54                          
  Glutamine (µmol/l)                        Control   20            241.82±12.93   100.00           0.001
  Autistic                                  20        111.34±5.69   46.04                           
  Glutamic/Glutamine Ratio                  Control   20            0.46±0.03      100.00           0.001
  Autistic                                  20        1.37±0.06     296.18                          
  Glutamate dehydrogenase (GLDH) (U/l)      Control   20            1.71±0.47      100.00           0.001
  Autistic                                  20        0.93±0.36     54.22                           
  Thioredoxin I (ng/ml)                     Control   20            44.71±7.43     100.00           0.001
  Autistic                                  20        74.70±9.04    167.09                          
  Thioredoxin reductase (mU/ml)             Control   20            1.83±0.52      100.00           0.001
  Autistic                                  20        3.31±1.11     180.87                          
  Peroxiredoxin I (ng/ml)                   Control   20            19.58±4.76     100.00           0.001
  Autistic                                  20        34.56±8.32    176.55                          
  Peroxiredoxin III (ng/ml)                 Control   20            24.30±2.69     100.00           0.001
  Autistic                                  20        43.05±5.86    177.16                          
  GSH/GSSG                                  Control   20            26.07±5.03     100.00           0.001
  Autistic                                  20        8.03±2.46     30.79                           
  Glutathione-s-transferase (µmol/min/ml)   Control   20            0.69±0.20      100.00           0.001
  Autistic                                  20        0.41±0.12     59.26                           
  Mercury (µg/L)                            Control   20            4.64±0.68      100.00           0.001
  Autistic                                  20        6.93±0.74     149.40                          
  ----------------------------------------- --------- ------------- -------------- ---------------- -----------

###### 

Multiple regression using stepwise method for glutamic acid (µmol/l) as a dependent variable in autistic group.

Table 2

  ------------------------------- ----------- ----------- ----------------- --------- -------
  Predictor variable              Beta        *P* value   Adjusted *R*^2^   Model     
  *F* value                       *P* value                                           
  Glutamine (µmol/l)              0.302       0.001       0.964             352.514   0.001
  Glutamic/glutamine ratio        92.604      0.001                                   
  Peroxiredoxin 1 level (ng/ml)   −0.273      0.011                                   
  ------------------------------- ----------- ----------- ----------------- --------- -------

###### 

Multiple regression using stepwise method for glutamine (µmol/l) as a dependent variable in autistic group.

Table 3

  ----------------------------- ----------- ----------- ------------------------ ---------- -------
  Predictor variable            Beta        *P* value   Adjusted *R*^2^ square   Model      
  *F* value                     *P* value                                                   
  Glutamic (µmol/l)             0.969       0.001       0.990                    1243.754   0.001
  Glutamic/glutamine ratio      −177.627    0.001                                           
  Thioredoxin 1 level (ng/ml)   −0.274      0.044                                           
  ----------------------------- ----------- ----------- ------------------------ ---------- -------

###### 

Multiple regression using stepwise method for glutamic/glutamine ratio as a dependent variable in autistic group.

Table 4

  ---------------------------------------- ----------- ----------- ----------------- ---------- -------
  Predictor variable                       Beta        *P* value   Adjusted *R*^2^   Model      
  *F* value                                *P* value                                            
  Glutamic (µmol/l)                        0.006       0.001       0.995             1938.823   0.001
  Glutamine (µmol/l)                       −0.005      0.001                                    
  Thioredoxin reductase activity (mU/ml)   0.013       0.038                                    
  GSH/GSSG                                 −0.003      0.018                                    
  ---------------------------------------- ----------- ----------- ----------------- ---------- -------

###### 

Multiple regression using stepwise method for glutamic (µmol/l) as a dependent variable in control group.

Table 5

  -------------------------- ----------- ----------- ----------------- --------- -------
  Predictor variable         Beta        *P* value   Adjusted *R*^2^   Model     
  *F* value                  *P* value                                           
  Glutamic/glutamine ratio   222.768     0.001       0.996             2481.60   0.001
  Glutamine (µmol/l)         0.445       0.001                                   
  -------------------------- ----------- ----------- ----------------- --------- -------
